A Clinical, Radiographic and Laboratory Evaluation of Prognostic Factors in 363 Patients with Malignant Pleural Mesothelioma

被引:59
作者
Tanrikulu, Abdullah Cetin [1 ]
Abakay, Abdurrahman
Kaplan, Mehmet Ali [2 ]
Kucukoner, Mehmet [2 ]
Palanci, Yilmaz [4 ]
Evliyaoglu, Osman [3 ]
Sezgi, Cengizhan
Sen, Hadice
Carkanat, Ali Ihsan
Kirbas, Gokhan
机构
[1] Dicle Univ, Sch Med, Dept Chest Dis, Diyarbakir, Turkey
[2] Dicle Univ, Dept Med Oncol, Diyarbakir, Turkey
[3] Dicle Univ, Dept Biochem, Diyarbakir, Turkey
[4] Dicle Univ, Dept Publ Hlth, Fac Med, Diyarbakir, Turkey
关键词
Asbestos exposure; Malignant pleural mesothelioma; C-reactive protein; C-REACTIVE PROTEIN; CELL LUNG-CANCER; FIBER EXPOSURE; SURVIVAL; TURKEY; ASBESTOS; EXPERIENCE; SOUTHEAST; EPIDEMIOLOGY; CHEMOTHERAPY;
D O I
10.1159/000321370
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Malignant pleural mesothelioma (MPM) has a poor prognosis. Objectives: Only few studies in literature investigated the presence of pleural fluid and radiographic findings for the prognosis of MPM. Methods: We retrospectively investigated the hospital charts of 363 MPM patients who were diagnosed from January 1989 to March 2010. Survival time was calculated by the Kaplan-Meier method. Pretreatment clinical, laboratory and radiographic features of each patient at the time of diagnosis were obtained from patients' charts. Results: The mean age of 363 patients (217 men, 146 women) was 50.6 +/- 11.2 years (range 19-85) and the mean survival time was 11.7 +/- 8.6 months (range 1-53). Histological types of MPM were epithelial (71.2%), mixed (15.9%) and sarcomatous type (4.9%). The frequency of disease stages were 31.4% for stage 1, 24.2% for stage 2, 28.6% for stage 3 and 15.8% for stage 4. The most frequent symptoms were dyspnea (82.1%), chest pain (68.3%) and weight loss (58.9%). Results of univariate and multivariate analyses revealed that a Karnofsky performance score <= 60, a pleural fluid glucose level <= 40 mg/dl, a C-reactive protein level > 50 mg/l, a serum lactate dehydrogenase level > 500 U/l, the presence of pleural fluid, pleural thickening > 1 cm and a platelet count of > 420 x 10(3)/mu l were found to be associated with poor prognosis in MPM. Conclusions: Our data suggest that low pleural fluid glucose and high C-reactive protein, the presence of pleural fluid and pleural thickening were associated with poor MPM prognosis. Further prospective studies are needed to highlight prognostic factors more clearly. Copyright (C) 2010 S. Karger AG, Basel
引用
收藏
页码:480 / 487
页数:8
相关论文
共 39 条
  • [21] LETOURNEUX M, 1993, EUR RESPIR REV, V3, P87
  • [22] MANZINI PV, 1993, CANCER, V72, P410
  • [23] Computed tomography features in malignant pleural mesothelioma and other commonly seen pleural diseases
    Metintas, M
    Ucgun, I
    Elbek, O
    Erginel, S
    Metintas, S
    Kolsuz, M
    Harmanci, E
    Alatas, F
    Hillerdal, G
    Ozkan, R
    Kaya, T
    [J]. EUROPEAN JOURNAL OF RADIOLOGY, 2002, 41 (01) : 1 - 9
  • [24] Prognostic factors in diffuse malignant pleural mesothelioma: effects of pretreatment clinical and laboratory characteristics
    Metintas, M
    Metintas, S
    Ucgun, I
    Gibbs, AR
    Harmanci, E
    Alatas, F
    Erginel, S
    Tel, N
    Pasaoglu, O
    [J]. RESPIRATORY MEDICINE, 2001, 95 (10) : 829 - 835
  • [25] Survival of pleural malignant mesothelioma in Italy: A population-based study
    Montanaro, Fabio
    Rosato, Rosalba
    Gangemi, Manuela
    Roberti, Sara
    Ricceri, Fulvio
    Merler, Enzo
    Gennaro, Valerio
    Romanelli, Antonio
    Chellini, Elisabetta
    Pascucci, Cristiana
    Musti, Marina
    Nicita, Carmela
    Barbieri, Pietro Gino
    Marinaccio, Alessandro
    Magnani, Corrado
    Mirabelli, Dario
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (01) : 201 - 207
  • [26] Malignant mesothelioma
    Moore, Alastair J.
    Parker, Robert J.
    Wiggins, John
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2008, 3 (1)
  • [27] The European mesothelioma epidemic
    Peto, J
    Decarli, A
    La Vecchia, C
    Levis, F
    Negri, E
    [J]. BRITISH JOURNAL OF CANCER, 1999, 79 (3-4) : 666 - 672
  • [28] Biomarkers for mesothelioma
    Scherpereel, Arnaud
    Lee, Y. C. Gary
    [J]. CURRENT OPINION IN PULMONARY MEDICINE, 2007, 13 (04) : 339 - 343
  • [29] Prognostic value of the serum tumour markers Cyfra 21-1 and tissue polypeptide antigen in malignant mesothelioma
    Schouwink, H
    Korse, CM
    Bonfrer, JMG
    Hart, AAM
    Baas, P
    [J]. LUNG CANCER, 1999, 25 (01) : 25 - 32
  • [30] MALIGNANT PLEURAL MESOTHELIOMA DUE TO ENVIRONMENTAL MINERAL FIBER EXPOSURE IN TURKEY - ANALYSIS OF 135 CASES
    SELCUK, ZT
    COPLU, L
    EMRI, S
    KALYONCU, AF
    SAHIN, AA
    BARIS, YI
    [J]. CHEST, 1992, 102 (03) : 790 - 796